Molecular Pathology Laboratory Network

HMW, LMW, Pankeratin

I CEA: CEA carcinoembryonic antigen
I CDX2: CDX2 colorectal carcinoma
I CK5/6: Cytokeratinj 5/6, positive squamous, mesothelial
I CK7: I CK HMW: 34BE12, Cytokeratin high molecular weight
I CK7: Cytokeratin 7, 54kD
I CAM5.2: Cytokeratin 8 (CAM5.2)
I CK8: Cytokeratin 8, 35BH11
I CK8/18: Cytokeratin 8/18
I CK19: Cytokeratin 19
I CK20: Cytokeratin 20
I D2 40: D2-40, Podoplanin
I GALECT: Galectin-3, thyroid neoplasm, anaplastic LCL
I THYRGLB: Thyroglobulin
I TTF1: Thyroid transcription factor-1, lung, thyroid
I GCDFP15: Gross cystic disease fluid protein 15
I HEPAR1: Hepatocyte antigen (HEP-Par-1), liver
I INHIB: Inhibin, adrenal cortical, sex chord stromal,
I PLAP: Placental alkaline phosphatase, germ cell tumors,
I RCC: Renal cell carcinoma

Immunohistochemistry

88342 each marker

Less than 2 days

Indefinitely at room temperature

Inadequate fixation; Improper labeling

Marker and tissue specific

Results are reviewed by a board-certified pathologist to determine if tissues are positive or negative for the marker. These results may be used to assist in determining appropriate patient therapy or treatment. Immunohistochemistry combines the principles of histochemistry with the high degree of molecular specificity of the antibody-antigen reaction. The use of an enhanced-polymer detection system provides many benefits including increased sensitivity, fewer procedural steps as compared to conventional techniques, and a reduction in non-specific background staining.

MPLN offers a range of markers by Immunohistochemistry including hematologic, tissue specific, infectious agents and proliferation antigens.